Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) reached a new 52-week high on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as ...

Benzinga's options scanner spotted 9 options trades for Madrigal Pharmaceuticals. This is not a typical pattern. The sentiment among these major traders is split, with 44% bullish and 44% bearish.

Three months ago, in its third-quarter report, Madrigal pointed out that it achieved a key goal early by gaining 80% coverage ...

Citizens JMP raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $443 from $427 and keeps an Outperform rating on the shares.

Oppenheimer raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $475 from $400 and keeps an Outperform rating on the shares ...

Alcoholic and non-alcoholic fatty liver disease (NAFLD) are well-known risk factors for colorectal cancer (CRC). NAFLD has ...

Bill Sibold, Madrigal Pharmaceuticals CEO , joins 'Fast Money' to talk quarterly results.

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...

Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and ...